Literature DB >> 22368686

What is the performance of the Aspartate Aminotransferase to platelets Ratio Index in patients With Chronic Liver Disease?

Jean Pierre Zarski1.   

Abstract

Entities:  

Keywords:  Aspartate Aminotransferase; End Stage Liver Disease

Year:  2011        PMID： 22368686      PMCID： PMC3282024          DOI： 10.5812/kowsar.1735143X.798

Source DB:  PubMed          Journal:  Hepat Mon        ISSN： 1735-143X            Impact factor:   0.660


× No keyword cloud information.
  4 in total

Review 1.  Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis.

Authors:  Zhong-Hua Lin; Yong-Ning Xin; Quan-Jiang Dong; Qing Wang; Xiang-Jun Jiang; Shu-Hui Zhan; Ying Sun; Shi-Ying Xuan
Journal:  Hepatology       Date:  2011-02-11       Impact factor: 17.425

2.  Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study.

Authors:  Jean-Pierre Zarski; Nathalie Sturm; Jérôme Guechot; Adeline Paris; Elie-Serge Zafrani; Tarik Asselah; Renée-Claude Boisson; Jean-Luc Bosson; Dominique Guyader; Jean-Charles Renversez; Jean-Pierre Bronowicki; Marie-Christine Gelineau; Albert Tran; Candice Trocme; Victor De Ledinghen; Elisabeth Lasnier; Armelle Poujol-Robert; Frédéric Ziegler; Marc Bourliere; Hélène Voitot; Dominique Larrey; Maria Alessandra Rosenthal-Allieri; Isabelle Fouchard Hubert; François Bailly; Michel Vaubourdolle
Journal:  J Hepatol       Date:  2011-07-23       Impact factor: 25.083

3.  A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

Authors:  Chun-Tao Wai; Joel K Greenson; Robert J Fontana; John D Kalbfleisch; Jorge A Marrero; Hari S Conjeevaram; Anna S-F Lok
Journal:  Hepatology       Date:  2003-08       Impact factor: 17.425

4.  Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease: APRI in chronic liver disease.

Authors:  Yusuf Yilmaz; Oya Yonal; Ramazan Kurt; Muharrem Bayrak; Bilge Aktas; Osman Ozdogan
Journal:  Hepat Mon       Date:  2011-02       Impact factor: 0.660
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.